GLP1R and obesity disorder: 2024) as well as strategies to mitigate AT aging (Wang et al. 2022). Additionally, it may be useful in assessing the impact of pharmacological treatments, particularly GLP‐1 receptor agonists, in promoting weight loss and metabolic improvements (Singh et al. 2022). Beyond obesity, this approach could be applied to study adipocyte morphological changes in pathological contexts, such as pericardial AT remodeling in myocardial infarction (Horckmans et al. 2018) or adipocyte function alterations associated with anorexia nervosa (Xiao et al. 2020).